Stock — Buy Pfizer

Potential buyers must weigh the value proposition against structural challenges that may limit near-term price appreciation:

: Pfizer remains a premier income stock, offering a 6.42% dividend yield . Management has reaffirmed its commitment to the dividend, declaring a $0.43 per share payout for the second quarter of 2026. While the payout ratio is elevated, management's cost-realignment program—targeting $7.2 billion in cumulative savings by 2027 —is intended to protect these cash returns.

The market currently views Pfizer through the lens of its "COVID hangover" and an impending "patent cliff." However, for long-term investors, the current valuation may represent an attractive entry point based on three primary pillars: buy pfizer stock

For , Pfizer may remain a "dead money" asset due to the lack of immediate revenue drivers. However, for long-term value and income investors , the stock offers a rare combination of a high, sustainable yield and the potential for a significant "re-rating" once the market gains confidence in its post-2028 growth engine.

AI responses may include mistakes. For financial advice, consult a professional. Learn more Potential buyers must weigh the value proposition against

: Trading at approximately 15x to 20x estimated earnings and significantly below its pandemic-era highs, the stock is considered undervalued by several analysts. With a market cap of roughly $153.59 billion , many argue the downside risk is cushioned by the existing pessimistic sentiment.

: Official 2026 guidance forecasts revenue between $59.5 billion and $62.5 billion , a slight decline from 2025 levels. This "soft" outlook has led many major brokerages, such as Bank of America and Bernstein , to maintain "Neutral" or "Hold" ratings. The market currently views Pfizer through the lens

: Pfizer anticipates a $1.5 billion revenue headwind in 2026 due to patent expirations, with these losses projected to accelerate to over $6 billion annually by 2028 .